ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer
R. Garnham, D. Geh, R. Nelson, E. Ramon-Gil, L. Wilson, E. N. Schmidt, L. Walker, B. Adamson, A. Buskin, A. Hepburn, K. Hodgson, H. Kendall, F. M. Frame, N. J. Maitland, K. Coffey, , E. Scott
This study shows ST3Gal1 promotes immune evasion in prostate cancer by synthesizing Siglec ligands, and its activity can be modulated by enzalutamide.
bioRxiv · Apr 3, 2023 · PreprintCancer Biology